Contributions
Abstract: EP1454
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Background: Fingolimod is an oral therapy for the relapsing MS, but disease progression may occur despite effective control of inflammation. Diffusion MRI (dMRI) provides quantitative measures of tissue integrity in normal appearing white matter and may provide useful predictive biomarkers of white matter injury that does not manifest on a routine neurological exam.
Goal: To detect evolution of white matter injury among patients undergoing treatment with fingolimod.
Methods: In this open-label, IRB-approved study, dMRI was performed at 3 tesla on 16 MS patients prior to, and 6, 12 and 18 months after initiating fingolimod treatment. Metrics of tissue integrity (radial diffusivity (RD), axial diffusivity (AD), fractional anisotropy (FA) and mean diffusivity (MD)) from dMRI were quantified in bilateral corticospinal tract (CST) and their mean values were calculated. A repeated measures analysis of variance (RANOVA) was performed to determine if significant changes in white matter integrity occurred along the time course of the treatment.
Results: Over time, significant changes were found in RD, MD and AD (p< 0.005, < 0.001, < 0.022 respectively). These changes were characterized by increase in RD, MD and AD values over the 18-month course of the treatment. The increase of RD was mostly seen during the 1st 12 months of the treatment.
Conclusions: dMRI suggests a decline in white matter integrity among MS patients undergoing fingolimod treatment. These results are useful in powering future longitudinal studies using dMRI.
Disclosure: Jian Lin: Part of Salary from a grant funded by Novartis
Pallab Bhattacharyya: Part of Salary from a grant funded by Novartis
Ken Sakaie: Salary support from Novartis and Genzyme
Robert Fox has received consultant fees from Biogen Idec, GlaxoSmithKline, Novartis, Questcor, Teva, and Xenoport; grant and research support from Novartis.
Mark Lowe receives consulting income from Siemens Medical Systems.
Abstract: EP1454
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Background: Fingolimod is an oral therapy for the relapsing MS, but disease progression may occur despite effective control of inflammation. Diffusion MRI (dMRI) provides quantitative measures of tissue integrity in normal appearing white matter and may provide useful predictive biomarkers of white matter injury that does not manifest on a routine neurological exam.
Goal: To detect evolution of white matter injury among patients undergoing treatment with fingolimod.
Methods: In this open-label, IRB-approved study, dMRI was performed at 3 tesla on 16 MS patients prior to, and 6, 12 and 18 months after initiating fingolimod treatment. Metrics of tissue integrity (radial diffusivity (RD), axial diffusivity (AD), fractional anisotropy (FA) and mean diffusivity (MD)) from dMRI were quantified in bilateral corticospinal tract (CST) and their mean values were calculated. A repeated measures analysis of variance (RANOVA) was performed to determine if significant changes in white matter integrity occurred along the time course of the treatment.
Results: Over time, significant changes were found in RD, MD and AD (p< 0.005, < 0.001, < 0.022 respectively). These changes were characterized by increase in RD, MD and AD values over the 18-month course of the treatment. The increase of RD was mostly seen during the 1st 12 months of the treatment.
Conclusions: dMRI suggests a decline in white matter integrity among MS patients undergoing fingolimod treatment. These results are useful in powering future longitudinal studies using dMRI.
Disclosure: Jian Lin: Part of Salary from a grant funded by Novartis
Pallab Bhattacharyya: Part of Salary from a grant funded by Novartis
Ken Sakaie: Salary support from Novartis and Genzyme
Robert Fox has received consultant fees from Biogen Idec, GlaxoSmithKline, Novartis, Questcor, Teva, and Xenoport; grant and research support from Novartis.
Mark Lowe receives consulting income from Siemens Medical Systems.